HK1077057A1 - Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases - Google Patents
Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinasesInfo
- Publication number
- HK1077057A1 HK1077057A1 HK05108425.3A HK05108425A HK1077057A1 HK 1077057 A1 HK1077057 A1 HK 1077057A1 HK 05108425 A HK05108425 A HK 05108425A HK 1077057 A1 HK1077057 A1 HK 1077057A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- processes
- protein kinases
- pyrimidine derivatives
- substituted pyrimidines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39065802P | 2002-06-20 | 2002-06-20 | |
US41160902P | 2002-09-18 | 2002-09-18 | |
PCT/US2003/019266 WO2004000833A1 (en) | 2002-06-20 | 2003-06-19 | Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1077057A1 true HK1077057A1 (en) | 2006-02-03 |
Family
ID=30003168
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05108425.3A HK1077057A1 (en) | 2002-06-20 | 2005-09-23 | Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases |
HK06100957.5A HK1081178A1 (en) | 2002-06-20 | 2006-01-20 | Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase |
HK07107925.8A HK1100081A1 (en) | 2002-06-20 | 2007-07-23 | Process for preparing substituted pyrimidines |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06100957.5A HK1081178A1 (en) | 2002-06-20 | 2006-01-20 | Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase |
HK07107925.8A HK1100081A1 (en) | 2002-06-20 | 2007-07-23 | Process for preparing substituted pyrimidines |
Country Status (27)
Country | Link |
---|---|
US (4) | US20040049032A1 (ja) |
EP (4) | EP1746093B1 (ja) |
JP (5) | JP4237701B2 (ja) |
KR (2) | KR101141959B1 (ja) |
CN (1) | CN100484934C (ja) |
AR (1) | AR040286A1 (ja) |
AT (2) | ATE498621T1 (ja) |
AU (1) | AU2003245568B2 (ja) |
BR (1) | BR0312443A (ja) |
CA (1) | CA2489824C (ja) |
CO (1) | CO5680433A2 (ja) |
DE (1) | DE60336092D1 (ja) |
EA (2) | EA012869B1 (ja) |
EC (1) | ECSP055561A (ja) |
ES (1) | ES2386781T3 (ja) |
HK (3) | HK1077057A1 (ja) |
HR (1) | HRP20050064A2 (ja) |
IL (1) | IL165849A0 (ja) |
IS (2) | IS7606A (ja) |
MX (1) | MXPA05000068A (ja) |
MY (1) | MY141867A (ja) |
NO (2) | NO331925B1 (ja) |
NZ (4) | NZ537720A (ja) |
PL (1) | PL374953A1 (ja) |
SG (1) | SG170614A1 (ja) |
TW (2) | TWI354554B (ja) |
WO (1) | WO2004000833A1 (ja) |
Families Citing this family (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1318997B1 (en) | 2000-09-15 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6653300B2 (en) * | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
SG159380A1 (en) * | 2002-02-06 | 2010-03-30 | Vertex Pharma | Heteroaryl compounds useful as inhibitors of gsk-3 |
AU2003218215A1 (en) | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
NZ538426A (en) | 2002-08-02 | 2007-05-31 | Vertex Pharma | Pyrazole compositions useful as inhibitors of glycogen synthase kinase-3 (GSK-3) |
US7601718B2 (en) * | 2003-02-06 | 2009-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
CN1902193B (zh) * | 2003-12-04 | 2011-07-13 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的喹喔啉 |
WO2005061519A1 (en) * | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
WO2005077938A1 (en) * | 2004-02-11 | 2005-08-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
RU2006139258A (ru) | 2004-04-08 | 2008-05-20 | Таргеджен, Инк. (US) | Бензотриазиновые ингибиторы киназ |
JP2007533753A (ja) * | 2004-04-23 | 2007-11-22 | タケダ サン ディエゴ インコーポレイテッド | インドール誘導体及びキナーゼ阻害剤としてのその使用 |
JP2008510734A (ja) * | 2004-08-18 | 2008-04-10 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
EP1799656A4 (en) | 2004-08-25 | 2009-09-02 | Targegen Inc | HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
US7285569B2 (en) | 2004-09-24 | 2007-10-23 | Hoff Hoffmann-La Roche Inc. | Tricycles, their manufacture and use as pharmaceutical agents |
TW200624431A (en) | 2004-09-24 | 2006-07-16 | Hoffmann La Roche | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents |
EP1812439B2 (en) * | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
JP2008520713A (ja) | 2004-11-17 | 2008-06-19 | ミイカナ セラピューティクス インコーポレイテッド | キナーゼ阻害剤 |
WO2006074057A2 (en) | 2004-12-30 | 2006-07-13 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
MX2007012477A (es) | 2005-04-14 | 2007-11-08 | Hoffmann La Roche | Derivados de aminopirazol, su fabricacion y uso como agentes farmaceuticos. |
US8071768B2 (en) * | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
US7825244B2 (en) * | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
CA2616517A1 (en) * | 2005-07-26 | 2007-02-01 | Vertex Pharmaceuticals Incorporated | Abl kinase inhibition |
ATE542814T1 (de) * | 2005-08-18 | 2012-02-15 | Vertex Pharma | Pyrazinkinaseinhibitoren |
KR20140025610A (ko) * | 2005-09-30 | 2014-03-04 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
BRPI0617489A2 (pt) | 2005-10-18 | 2011-07-26 | Janssen Pharmaceutica Nv | compostos, composiÇço e uso de ditos compostos para inibir a flt3 cinase |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
AU2013201630B2 (en) * | 2005-11-03 | 2016-12-01 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
AR056764A1 (es) * | 2005-11-03 | 2007-10-24 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de quinasa |
CN101360740A (zh) * | 2005-11-16 | 2009-02-04 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶 |
WO2007120339A1 (en) * | 2005-12-19 | 2007-10-25 | Genentech, Inc. | Pyrimidine kinase inhibitors |
EP1984353B1 (en) | 2006-01-23 | 2015-12-30 | Amgen, Inc | Aurora kinase modulators and method of use |
US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
WO2007087246A2 (en) * | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Jak2 tyrosine kinase inhibition |
US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
DK2021335T3 (da) | 2006-04-20 | 2011-09-05 | Janssen Pharmaceutica Nv | Heterocykliske forbindelser som C-FMS-kinasehæmmere |
NZ572071A (en) | 2006-04-20 | 2011-12-22 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase |
US7615627B2 (en) | 2006-06-21 | 2009-11-10 | Reliance Life Sciences Pvt. Ltd. | RNA interference mediated inhibition of aurorakinase B and its combinations as anticancer therapy |
US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
GB0619343D0 (en) * | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
US8236823B2 (en) | 2006-10-27 | 2012-08-07 | Amgen Inc. | Multi-cyclic compounds and methods of use |
ATE457311T1 (de) * | 2006-11-02 | 2010-02-15 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine |
ATE474835T1 (de) * | 2006-12-19 | 2010-08-15 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete aminopyrimidine |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
AU2008226461A1 (en) * | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyridines useful as inhibitors of protein kinases |
EP2134707B1 (en) * | 2007-03-09 | 2013-09-11 | Vertex Pharmaceuticals, Inc. | Aminopyrimidines useful as inhibitors of protein kinases |
MX2009009591A (es) * | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
CA2682195A1 (en) * | 2007-03-20 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
AU2008236670B2 (en) | 2007-04-05 | 2011-12-01 | Amgen Inc. | Aurora kinase modulators and method of use |
CN101679386A (zh) * | 2007-04-13 | 2010-03-24 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶类化合物 |
CA2688584A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
MX2009011810A (es) | 2007-05-02 | 2010-01-14 | Vertex Pharma | Tiazoles y pirazoles utiles como inhibidores de cinasa. |
WO2008137621A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
CN101687852A (zh) * | 2007-05-24 | 2010-03-31 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的噻唑类和吡唑类化合物 |
JP2010529193A (ja) * | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
JP5553751B2 (ja) | 2007-07-31 | 2014-07-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | 5−フルオロ−1H−ピラゾロ[3,4−b]ピリジン−3−アミンおよびその誘導体を調製するためのプロセス |
KR20100080597A (ko) | 2007-09-14 | 2010-07-09 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | 1,3-이치환된-4-페닐-1h-피리딘-2-온 |
US9114138B2 (en) | 2007-09-14 | 2015-08-25 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones |
KR20100065191A (ko) | 2007-09-14 | 2010-06-15 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | 1,3-이치환된 4-(아릴-x-페닐)-1h-피리딘-2-온 |
JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
WO2009062676A2 (en) | 2007-11-14 | 2009-05-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
WO2009065232A1 (en) * | 2007-11-20 | 2009-05-28 | University Health Network | Cancer diagnostic and therapeutic methods that target plk4/sak |
WO2009073224A1 (en) * | 2007-12-07 | 2009-06-11 | Ambit Biosciences Corp. | Methods of treating certain diseases using pyrimidine derivatives |
WO2009086012A1 (en) * | 2007-12-20 | 2009-07-09 | Curis, Inc. | Aurora inhibitors containing a zinc binding moiety |
EP2288611B1 (en) | 2008-03-20 | 2013-05-15 | Amgen Inc. | Aurora kinase modulators and method of use |
US9126935B2 (en) | 2008-08-14 | 2015-09-08 | Amgen Inc. | Aurora kinase modulators and methods of use |
RU2510396C2 (ru) | 2008-09-02 | 2014-03-27 | Янссен Фармасьютикалз, Инк. | 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов |
AU2009288200A1 (en) * | 2008-09-03 | 2010-03-11 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
BRPI0918970A2 (pt) * | 2008-09-05 | 2019-09-24 | Avila Therapeutics Inc | algoritmo para projeto de inibidores irreversíveis |
US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
AR074210A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
BRPI0921333A2 (pt) | 2008-11-28 | 2015-12-29 | Addex Pharmaceuticals Sa | derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos |
RU2535032C2 (ru) | 2008-12-22 | 2014-12-10 | Милленниум Фармасьютикалз, Инк. | Сочетание ингибиторов аврора киназы и анти-cd 20 антител |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
NZ596053A (en) | 2009-05-12 | 2013-05-31 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
SG176021A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
WO2011034907A2 (en) | 2009-09-16 | 2011-03-24 | Avila Therapeutics, Inc. | Protein kinase conjugates and inhibitors |
TW201134825A (en) | 2009-12-30 | 2011-10-16 | Avila Therapeutics Inc | Ligand-directed covalent modification of protein |
WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
PT2649069E (pt) | 2010-11-08 | 2015-11-20 | Janssen Pharmaceuticals Inc | Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2 |
EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
WO2012112674A2 (en) * | 2011-02-15 | 2012-08-23 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
CN104024246B (zh) * | 2012-03-27 | 2016-03-02 | 广东东阳光药业有限公司 | 作为欧若拉激酶抑制剂的取代嘧啶衍生物 |
US9296701B2 (en) | 2012-04-24 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
WO2013177367A2 (en) | 2012-05-23 | 2013-11-28 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
AU2013271731A1 (en) * | 2012-06-07 | 2014-12-18 | Georgia State University Research Foundation, Inc. | SecA inhibitors and methods of making and using thereof |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
AU2013299922B2 (en) | 2012-08-07 | 2018-06-21 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
JP6407504B2 (ja) | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. | 恒常的に活性であるリン酸化型flt3キナーゼの阻害方法 |
EP2914265A4 (en) | 2012-11-05 | 2016-04-13 | Nant Holdings Ip Llc | SUBSTITUTED INDOL-5-OL COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS |
CN103202843B (zh) * | 2012-12-31 | 2015-04-29 | 刘强 | 一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途 |
BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
EP2964221B1 (en) | 2013-03-04 | 2017-12-06 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2014134774A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2014134772A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2014134776A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
DK3527563T3 (da) | 2013-03-12 | 2021-12-06 | Vertex Pharma | Dna-pk-inhibitorer |
US9550760B2 (en) * | 2013-03-15 | 2017-01-24 | Nantbioscience, Inc. | Substituted indol-5-ol derivatives and their therapeutic applications |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
CN105814036B (zh) | 2013-10-17 | 2018-10-26 | 沃泰克斯药物股份有限公司 | 作为dna-pk抑制剂的共晶 |
US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
JP6525474B2 (ja) | 2013-12-06 | 2019-06-05 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | オーロラキナーゼ阻害剤と抗cd30抗体の併用 |
SI3431106T1 (sl) | 2014-01-21 | 2021-03-31 | Janssen Pharmaceutica Nv | Kombinacije, ki vsebujejo pozitivne alosterične modulatorje metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba |
DK3096790T3 (da) | 2014-01-21 | 2019-10-07 | Janssen Pharmaceutica Nv | Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse |
WO2016067803A1 (ja) * | 2014-10-30 | 2016-05-06 | 富士フイルム株式会社 | 有機アミン塩及びその製造方法、並びに、アゾ色素の製造方法 |
CA2982890C (en) | 2015-04-17 | 2023-08-22 | Ludwig Institute For Cancer Research Ltd | Plk4 inhibitors |
US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
CA3038657A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
CN108778276A (zh) | 2016-11-02 | 2018-11-09 | 安罗格制药有限责任公司 | 用于治疗flt3突变型增殖性疾患相关突变的克莱拉尼 |
EA036668B1 (ru) | 2017-01-23 | 2020-12-07 | Кадент Терапеутикс, Инк. | Модуляторы калиевых каналов |
CN108250191B (zh) * | 2018-03-15 | 2020-10-20 | 兰州大学 | 一种3,5-二取代的2-氨基-吡嗪化合物及其制备工艺与应用 |
WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
WO2020049208A1 (es) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida |
CN113226466A (zh) | 2018-10-22 | 2021-08-06 | 科登特治疗公司 | 钾通道调节剂的结晶形式 |
US20220305048A1 (en) | 2019-08-26 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
WO2023196959A1 (en) | 2022-04-07 | 2023-10-12 | Eli Lilly And Company | Process for making a kras g12c inhibitor |
WO2023196887A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
US20240108618A1 (en) | 2022-06-30 | 2024-04-04 | Eli Lilly And Company | Kras g12c inhibitor dosing regimens |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133081A (en) * | 1964-05-12 | J-aminoindazole derivatives | ||
US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
BE754242A (fr) * | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
US3939183A (en) * | 1973-10-05 | 1976-02-17 | Chevron Research Company | Purification of maleic anhydride |
US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
GB1446126A (en) | 1974-05-16 | 1976-08-18 | Res Inst For Medicine Chemistr | Photolytic preparation of diol mononitrates |
DE2458965C3 (de) * | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
MA18829A1 (fr) | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
DE2922436A1 (de) | 1979-06-01 | 1980-12-18 | Sueddeutsche Kalkstickstoff | Verfahren zur gewinnung von harnstoffkoernern mit verbesserten eigenschaften |
DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
SE8102194L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
JPS58124773A (ja) * | 1982-01-20 | 1983-07-25 | Mitsui Toatsu Chem Inc | 5−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤 |
US4477450A (en) * | 1983-03-03 | 1984-10-16 | Riker Laboratories, Inc. | Triazolo [4,3-c]pyrimidines substituted by nitrogen-containing heterocyclic rings |
EP0136976A3 (de) | 1983-08-23 | 1985-05-15 | Ciba-Geigy Ag | Verwendung von Phenylpyrimidinen als Pflanzenregulatoren |
NO157836C (no) | 1985-04-19 | 1988-05-25 | Jacobsen As J | Anordning ved asymmetrisk belysning. |
DE3725638A1 (de) | 1987-08-03 | 1989-02-16 | Bayer Ag | Neue aryloxy (bzw. thio)aminopyrimidine |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5597920A (en) | 1992-04-30 | 1997-01-28 | Neurogen Corporation | Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes |
JPH0665237A (ja) | 1992-05-07 | 1994-03-08 | Nissan Chem Ind Ltd | 置換ピラゾール誘導体および農園芸用殺菌剤 |
HU212308B (en) * | 1992-06-09 | 1996-05-28 | Richter Gedeon Vegyeszet | Process for producing novel pregnane steroids and pharmaceutical compositions containing the same |
ES2262137T3 (es) | 1993-10-01 | 2006-11-16 | Novartis Ag | Derivados de pirimidinamina farmacologicamente activos y procedimientos para su preparacion. |
CN1165482A (zh) * | 1994-11-10 | 1997-11-19 | 科西雷佩蒂斯公司 | 用作蛋白激酶抑制剂的吡唑药物组合物 |
IL117659A (en) * | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
US5935966A (en) | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
CA2230896A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
JPH10130150A (ja) | 1996-09-05 | 1998-05-19 | Dainippon Pharmaceut Co Ltd | 酢酸アミド誘導体からなる医薬 |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
DE69732780T2 (de) | 1996-10-02 | 2006-04-06 | Novartis Ag | Pyrimiderivate und verfahren zu ihrer herstellung |
BR9712530A (pt) | 1996-10-11 | 1999-10-19 | Warner Lambert Co | Inibidores de ésteres de asparato de enzima de conversão de interleucina-1beta |
CA2306692C (en) | 1997-10-10 | 2010-09-21 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
US6267952B1 (en) * | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
JP2000026421A (ja) | 1998-01-29 | 2000-01-25 | Kumiai Chem Ind Co Ltd | ジアリ―ルスルフィド誘導体及び有害生物防除剤 |
KR20010041015A (ko) * | 1998-02-17 | 2001-05-15 | 윌리엄 제이. 리플린 | 항바이러스성 피리미딘 유도체 |
EP1076563B1 (en) | 1998-03-16 | 2005-05-11 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
OA12147A (en) | 1998-06-02 | 2006-05-05 | Osi Pharm Inc | PyrroloÄ2,3dÜpyrimidine compositions and their use. |
WO1999065897A1 (en) | 1998-06-19 | 1999-12-23 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
EP1105394A1 (en) * | 1998-08-21 | 2001-06-13 | Du Pont Pharmaceuticals Company | ISOXAZOLO 4,5-d]PYRIMIDINES AS CRF ANTAGONISTS |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
JP2002527436A (ja) | 1998-10-08 | 2002-08-27 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
AU2457201A (en) * | 1999-12-28 | 2001-07-09 | Bristol-Myers Squibb Company | Cytokine, especially tnf-alpha, inhibitors |
US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
HUP0202332A2 (en) * | 2000-02-05 | 2002-10-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of erk |
AU3704101A (en) * | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
MXPA02010693A (es) * | 2000-04-28 | 2003-03-10 | Tanabe Seiyaku Co | Compuestos ciclicos. |
ATE394102T1 (de) * | 2000-06-28 | 2008-05-15 | Astrazeneca Ab | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CA2422376A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use as inhibitors of erk |
US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1318997B1 (en) * | 2000-09-15 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6641579B1 (en) * | 2000-09-29 | 2003-11-04 | Spectrasonics Imaging, Inc. | Apparatus and method for ablating cardiac tissue |
DE10061863A1 (de) * | 2000-12-12 | 2002-06-13 | Basf Ag | Verfahren zur Herstellung von Triethylendiamin (TEDA) |
US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
US6653300B2 (en) * | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
EP1373257B9 (en) * | 2001-03-29 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
ATE339416T1 (de) * | 2001-04-13 | 2006-10-15 | Vertex Pharma | Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen |
AU2002305205A1 (en) * | 2001-04-20 | 2002-11-05 | Jingrong Cao | 9-deazaguanine derivatives as inhibitors of gsk-3 |
EP1404669A2 (en) * | 2001-05-16 | 2004-04-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
CA2450769A1 (en) * | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
WO2003004492A1 (en) * | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
US6569499B2 (en) * | 2001-10-02 | 2003-05-27 | Xerox Corporation | Apparatus and method for coating photoreceptor substrates |
WO2003049739A1 (en) * | 2001-12-07 | 2003-06-19 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as gsk-3 inhibitors |
US7179826B2 (en) * | 2002-03-15 | 2007-02-20 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
AU2003218215A1 (en) * | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
US7091343B2 (en) * | 2002-03-15 | 2006-08-15 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
ATE365733T1 (de) * | 2002-03-15 | 2007-07-15 | Vertex Pharma | Zusammensetzungen brauchbar als protein-kinase- inhibitoren |
US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
WO2003091246A1 (en) * | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
JP4570955B2 (ja) * | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
NZ538426A (en) | 2002-08-02 | 2007-05-31 | Vertex Pharma | Pyrazole compositions useful as inhibitors of glycogen synthase kinase-3 (GSK-3) |
KR20140025610A (ko) | 2005-09-30 | 2014-03-04 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
ATE474835T1 (de) | 2006-12-19 | 2010-08-15 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete aminopyrimidine |
-
2003
- 2003-06-16 MY MYPI20032232A patent/MY141867A/en unknown
- 2003-06-18 US US10/464,430 patent/US20040049032A1/en not_active Abandoned
- 2003-06-19 WO PCT/US2003/019266 patent/WO2004000833A1/en active Application Filing
- 2003-06-19 CN CNB038188880A patent/CN100484934C/zh not_active Expired - Fee Related
- 2003-06-19 PL PL03374953A patent/PL374953A1/xx unknown
- 2003-06-19 EP EP06020384A patent/EP1746093B1/en not_active Expired - Lifetime
- 2003-06-19 AT AT06020384T patent/ATE498621T1/de not_active IP Right Cessation
- 2003-06-19 AR ARP030102187A patent/AR040286A1/es unknown
- 2003-06-19 NZ NZ537720A patent/NZ537720A/en not_active IP Right Cessation
- 2003-06-19 SG SG200608886-8A patent/SG170614A1/en unknown
- 2003-06-19 CA CA2489824A patent/CA2489824C/en not_active Expired - Fee Related
- 2003-06-19 EP EP03739195A patent/EP1517905B1/en not_active Expired - Lifetime
- 2003-06-19 NZ NZ576752A patent/NZ576752A/en not_active IP Right Cessation
- 2003-06-19 AU AU2003245568A patent/AU2003245568B2/en not_active Ceased
- 2003-06-19 EA EA200500053A patent/EA012869B1/ru not_active IP Right Cessation
- 2003-06-19 NZ NZ549142A patent/NZ549142A/en unknown
- 2003-06-19 MX MXPA05000068A patent/MXPA05000068A/es unknown
- 2003-06-19 ES ES03739195T patent/ES2386781T3/es not_active Expired - Lifetime
- 2003-06-19 EA EA200801372A patent/EA015990B1/ru not_active IP Right Cessation
- 2003-06-19 KR KR1020107028539A patent/KR101141959B1/ko not_active IP Right Cessation
- 2003-06-19 NZ NZ562953A patent/NZ562953A/en not_active IP Right Cessation
- 2003-06-19 EP EP10183009A patent/EP2292614A1/en not_active Withdrawn
- 2003-06-19 KR KR1020047020794A patent/KR101067254B1/ko not_active IP Right Cessation
- 2003-06-19 EP EP10182211A patent/EP2277876A1/en not_active Withdrawn
- 2003-06-19 BR BR0312443-6A patent/BR0312443A/pt not_active IP Right Cessation
- 2003-06-19 AT AT03739195T patent/ATE556068T1/de active
- 2003-06-19 DE DE60336092T patent/DE60336092D1/de not_active Expired - Lifetime
- 2003-06-19 JP JP2004515904A patent/JP4237701B2/ja not_active Expired - Fee Related
- 2003-06-20 TW TW092116828A patent/TWI354554B/zh not_active IP Right Cessation
- 2003-06-20 TW TW096112205A patent/TWI297684B/zh not_active IP Right Cessation
-
2004
- 2004-12-19 IL IL16584904A patent/IL165849A0/xx unknown
- 2004-12-20 IS IS7606A patent/IS7606A/is unknown
-
2005
- 2005-01-11 NO NO20050144A patent/NO331925B1/no not_active IP Right Cessation
- 2005-01-20 HR HR20050064A patent/HRP20050064A2/xx not_active Application Discontinuation
- 2005-01-20 EC EC2005005561A patent/ECSP055561A/es unknown
- 2005-01-20 CO CO05004362A patent/CO5680433A2/es not_active Application Discontinuation
- 2005-01-21 IS IS7661A patent/IS7661A/is unknown
- 2005-07-21 JP JP2005211959A patent/JP4662823B2/ja not_active Expired - Fee Related
- 2005-09-23 HK HK05108425.3A patent/HK1077057A1/xx not_active IP Right Cessation
-
2006
- 2006-01-20 HK HK06100957.5A patent/HK1081178A1/xx not_active IP Right Cessation
- 2006-08-09 US US11/500,981 patent/US7557106B2/en not_active Expired - Fee Related
-
2007
- 2007-07-23 HK HK07107925.8A patent/HK1100081A1/xx not_active IP Right Cessation
-
2009
- 2009-05-06 US US12/436,407 patent/US8268829B2/en not_active Expired - Fee Related
-
2010
- 2010-06-23 JP JP2010143228A patent/JP2010235626A/ja not_active Withdrawn
- 2010-06-23 JP JP2010143227A patent/JP2010202673A/ja not_active Withdrawn
-
2011
- 2011-04-05 NO NO20110523A patent/NO20110523L/no unknown
-
2012
- 2012-08-15 US US13/585,861 patent/US8779127B2/en not_active Expired - Fee Related
-
2014
- 2014-03-14 JP JP2014051076A patent/JP2014111662A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1077057A1 (en) | Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases | |
SI1562589T1 (sl) | Diaminotriazoli, koristni kot inhibitorji proteinkinaz | |
AU2003251559A8 (en) | Heterocyclic inhibitors of kinases | |
HK1160859A1 (en) | Inhibitors of tyrosine kinases | |
EP1560582A4 (en) | AZAINDOL DERIVATIVES AS INHIBITORS OF THE p38 KINASE | |
HUP0201935A3 (en) | Purine derivatives inhibitors of tyrosine protein kinase syk | |
HK1099764A1 (en) | Quinoxalines useful as inhibitors of protein kinases | |
HK1089448A1 (en) | Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases | |
HK1092723A1 (en) | Pyrazole derivatives as inhibitors of receptor tyrosine kinases | |
ZA200802998B (en) | Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases | |
EP1534290A4 (en) | NEW KINASE-HEMMER | |
SG153875A1 (en) | Pyrimidine urea derivatives as kinase inhibitors | |
AU2003233455A1 (en) | Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors | |
HK1077520A1 (zh) | 用作p38促細胞分裂原活化蛋白激酶抑制劑的吲哚類衍生物 | |
AU2003247141A1 (en) | 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases | |
HUP0303159A3 (en) | Crystal of pyrimidine nucleoside derivative | |
ZA200500414B (en) | Process for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinases | |
ZA200500492B (en) | Novel inhibitors of kinases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160619 |